Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder

Clinical Cancer Research

Volumn 11, Issue 12, 2005, Pages 4415-4429

  Wild, Peter J ^a   Herr, Alexander ^b   Wissmann, Christoph ^d   Stoehr, Robert ^a   Rosenthal, Andre ^e   Zaak, Dirk ^f   Simon, Ronald ^g   Knuechel, Ruth ^h   Pilarsky, Christian ^c   Hartmann, Arndt ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

^e Signature Diagnostics AG   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g UNIVERSITY OF BASEL   (Switzerland)

^h UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN E; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; MALE; PRIORITY JOURNAL; TISSUE MICROARRAY; TUMOR GROWTH;

AGED; ANALYSIS OF VARIANCE; CARCINOMA, PAPILLARY; CATHEPSIN E; CLUSTER ANALYSIS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LASERS; MALE; MICRODISSECTION; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 20444461984     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0259     Document Type: Article

References (50)

1. Dalesio O, Schulman CC, Sylvester R, et al. Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J Urol 1983;129:730-3.
2. Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-48.
3. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-6.
4. Kiemeney LA, Witjes JA, Heijbroek RP, Verbeek AL, Debruyne FM. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;150:60-4.
5. Althausen AF, Prout GR Jr, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976;116:575-80.
6. Cordon-Cardo C, Zhang ZF, Dalbagni G, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997;57:1217-21.
7. Cote RJ, Dunn MD, Chatterjee SJ, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090-4.
8. Masters JR, Vani UD, Grigor KM, et al. Can p53 staining be used to identify patients with aggressive superficial bladder cancer? J Pathol 2003;200:74-81.
9. Sarkis AS, Dalbagni G, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 1993;85:53-9.
10. Harnden P, Mahmood N, Southgate J. Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet 1999;353:974-7.
11. van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH, Zwarthoff EC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 2001;61:1265-8.
12. van Rhijn BW, Vis AN, van der Kwast TH, et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003;21:1912-21.
13. Dyrskjot L. Classification of bladder cancer by microarray expression profiling: towards a general clinical use of microarrays in cancer diagnostics. Expert Rev Mol Diagn 2003;3:635-47.
14. Sanchez-Carbayo M, Socci ND, Lozano JJ, et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol 2003;163:505-16.
15. Sanchez-Carbayo M, Socci ND, Charytonowicz E, et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res 2002;62:6973-80.
16. Duggan BJ, McKnight JJ, Williamson KE, et al. The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. Clin Cancer Res 2003;9:1240-7.
17. Thykjaer T, Workman C, Kruhoffer M, et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res 2001;61:2492-9.
18. Ying-Hao S, Qing Y, Lin-Hui W, et al. Monitoring gene expression profile changes in bladder transitional cell carcinoma using cDNA microarray. Urol Oncol 2002;7:207-12.
19. Dyrskjot L, Thykjaer T, Kruhoffer M, et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 2003;33:90-6.
20. Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res 2004;64:4040-8.
21. Mor O, Nativ O, Stein A, et al. Molecular analysis of transitional cell carcinoma using cDNA microarray. Oncogene 2003;22:7702-10.
22. Modlich O, Prisack HB, Pitschke G, et al. Identifying superficial, muscle-invasive, and metastasizing transitional cell carcinoma of the bladder: use of cDNA array analysis of gene expression profiles. Clin Cancer Res 2004;10:3410-21.
23. Schmitt AO, Specht T, Beckmann G, et al. Exhaustive mining of EST libraries for genes differentially expressed in normal and tumour tissues. Nucleic Acids Res 1999;27:4251-60.
24. Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004.
25. Wild P, Knuechel R, Dietmaier W, Hofstaedter F, Hartmann A. Laser microdissection and microsatellite analyses of breast cancer reveal a high degree of tumor heterogeneity. Pathobiology 2000;68:180-90.
26. Grutzmann R, Foerder M, Alldinger I, et al. Gene expression profiles of microdissected pancreatic ductal adenocarcinoma. Virchows Arch 2003.
27. Huber PJ. Robust statistics. New York: Wiley; 1981.
28. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
29. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002;18:207-8.
30. Simon R, Atefy R, Wagner U, et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer 2003;107:764-72.
31. Nocito A, Bubendorf L, Maria Tinner E, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 2001;194:349-57.
32. Wang E, Miller LD, Ohnmacht GA, Liu ET, Marincola FM. High-fidelity mRNA amplification for gene profiling. Nat Biotechnol 2000;18:457-9.
33. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990;322:1129-38.
34. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503-11.
35. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-82.
36. Tan NS, Shaw NS, Vinckenbosch N, et al. Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol 2002;22:5114-27.
37. Yoshimura R, Matsuyama M, Segawa Y, et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer 2003;104:597-602.
38. Gromova I, Gromov P, Wolf H, Cells JE. Protein abundancy and mRNA levels of the adipocyte-type fatty acid binding protein correlate in non-invasive and invasive bladder transitional cell carcinomas. Int J Oncol 1998;13:379-83.
39. Celis JE, Ostergaard M, Basse B, et al. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 1996;56:4782-90.
40. Baxa CA, Sha RS, Buelt MK, et al. Human adipocyte lipid-binding protein: purification of the protein and cloning of its complementary DNA. Biochemistry 1989;28:8683-90.
41. Bennett JH, Shousha S, Puddle B, Athanasou NA. Immunohistochemical identification of tumours of adipocytic differentiation using an antibody to aP2 protein. J Clin Pathol 1995;48:950-4.
42. Samloff IM, Taggart RT, Shiraishi T, et al. Slow moving proteinase. Isolation, characterization, and immunohistochemical localization in gastric mucosa. Gastroenterology 1987;93:77-84.
43. Matsuo K, Kobayashi I, Tsukuba T, et al. Immunohistochemical localization of cathepsins D and E in human gastric cancer: a possible correlation with local invasive and metastatic activities of carcinoma cells. Hum Pathol 1996;27:184-90.
44. Tenti P, Romagnoli S, Silini E, et al. Cervical adenocarcinomas express markers common to gastric, intestinal, and pancreatobiliary epithelial cells. Pathol Res Pract 1994;190:342-9.
45. Uno K, Azuma T, Nakajima M, et al. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol 2000;15:1333-8.
46. Tsukuba T, Okamoto K, Yasuda Y, Morikawa W, Nakanishi H, Yamamoto K. New functional aspects of cathepsin D and cathepsin E. Mol Cells 2000;10:601-11.
47. Bosi F, Silini E, Luisetti M, et al. Aspartic proteinases in normal lung and interstitial pulmonary diseases. Am J Respir Cell Mol Biol 1993;8:626-32.
48. Medd PG, Chain BM. Protein degradation in MHC class II antigen presentation: opportunities for immunomodulation. Semin Cell Dev Biol 2000;11:203-10.
49. Yamamoto S, Yonezawa S, Ichinose M, et al. Immunohistochemically demonstrated variation in expression of cathepsin E between uracil-induced papillomatosis and N-butyl-N-(4-hydroxybutyl)nitrosamine-induced preneoplastic and neoplastic changes in rat urinary bladder. Virchows Arch 1996;427:589-94.
50. Orntoft TF, Thykjaer T, Waldman FM, Wolf H, Celis JE. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. Mol Cell Proteomics 2002;1:37-45.